Shield Therapeutics plc
STX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £16,540 | £15,531 | £9,592 | £6,984 |
| % Growth | 6.5% | 61.9% | 37.3% | – |
| Cost of Goods Sold | £8,921 | £8,831 | £5,278 | £6,002 |
| Gross Profit | £7,619 | £6,700 | £4,315 | £982 |
| % Margin | 46.1% | 43.1% | 45% | 14.1% |
| R&D Expenses | £571 | £879 | £595 | £1,098 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £11,513 | £12,685 | £14,876 | £15,746 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £638 | £0 | £0 |
| Operating Expenses | £12,085 | £14,203 | £15,471 | £16,844 |
| Operating Income | -£4,466 | -£6,864 | -£11,156 | -£15,862 |
| % Margin | -27% | -44.2% | -116.3% | -227.1% |
| Other Income/Exp. Net | -£2,765 | -£1,717 | -£1,083 | -£564 |
| Pre-Tax Income | -£7,231 | -£8,581 | -£12,239 | -£16,426 |
| Tax Expense | £122 | £487 | -£2 | £85 |
| Net Income | -£7,353 | -£9,067 | -£12,238 | -£16,511 |
| % Margin | -44.5% | -58.4% | -127.6% | -236.4% |
| EPS | -0.007 | -0.012 | -0.016 | -0.022 |
| % Growth | 38.8% | 25.6% | 29.7% | – |
| EPS Diluted | -0.007 | -0.012 | -0.016 | -0.022 |
| Weighted Avg Shares Out | 1,041,690 | 782,056 | 782,056 | 742,190 |
| Weighted Avg Shares Out Dil | 1,041,690 | 782,056 | 782,056 | 742,190 |
| Supplemental Information | – | – | – | – |
| Interest Income | £130 | £49 | £161 | £153 |
| Interest Expense | £2,896 | £1,800 | £1,285 | £785 |
| Depreciation & Amortization | £546 | £638 | £475 | £437 |
| EBITDA | -£3,790 | -£6,142 | -£10,479 | -£15,638 |
| % Margin | -22.9% | -39.5% | -109.2% | -223.9% |